Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with …

Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …

Purpose It was aimed to determine the aggregated risk of MACE (major adverse
cardiovascular events) in stable CAD patients carrying CYP2C19 LoF alleles taking …

The aggregated risk of major adverse cardiovascular events (MACE) in acute coronary
syndrome (ACS) patients inheriting CYP2C19 loss-of function (LoF) alleles who underwent …

Background—The degree to which cytochrome P450 (CYP) 2C19 genotype influences the
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …

Background: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after
percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of …

Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous
coronary intervention (PCI) improves clinical outcomes. Although results for the increased …

Background: CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after
percutaneous coronary intervention, but the clinical impact of implementing CYP2C19 …

The effect of CYP2C19 gene polymorphism on clinical outcomes of patients with coronary
artery disease (CAD) treated with clopidogrel remains controversial. Ethnicity has been …

Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …